T-cell Redirection in Oncology: CAR T and Bispecific T-Cell Engagers

This technical report discusses the advancements in T-cell directed therapies in oncology, focusing on chimeric antigen receptor T-cell therapies (CAR T) and bispecific T-cell engagers (bispecific TCEs). It outlines the similarities and differences between these two modalities, particularly in their efficacy, safety profiles, and logistical considerations. CAR T therapies have shown higher efficacy and the potential for one-time dosing, while bispecific TCEs are easier to manage and have a lower resource burden, making them more accessible in non-academic hospital settings. The report also highlights the current market dynamics, projecting significant growth for both CAR T and bispecific TCEs in the coming years. It emphasizes the importance of innovation in bridging the efficacy gap and improving safety for both modalities, especially as they aim to address challenges in treating solid tumors. The document serves as a resource for biotech and pharmaceutical companies to evaluate their strategies in T-cell redirecting therapies.